Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis

Journal of Medicinal Chemistry

Volumn 60, Issue 9, 2017, Pages 3703-3726

  Hong, W David ^a,b   Gibbons, Peter D ^a,b   Leung, Suet C ^b   Amewu, Richard ^c   Stocks, Paul A ^b   Stachulski, Andrew ^b   Horta, Pedro ^d   Cristiano, Maria L S ^d   Shone, Alison E ^e   Moss, Darren ^f   Ardrey, Alison ^e   Sharma, Raman ^e   Warman, Ashley J ^e   Bedingfield, Paul T P ^e   Fisher, Nicholas E ^e   Aljayyoussi, Ghaith ^e   Mead, Sally ^e   Caws, Maxine ^e   Berry, Neil G ^b   Ward, Stephen A ^e   Biagini, Giancarlo A ^e   O’Neill, Paul M ^b   Nixon, Gemma L ^b   more..

^a University of Liverpool ^*

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF GHANA   (Ghana)

^d UNIVERSITY OF ALGARVE   (Portugal)

^e LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^f KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (5,7 DIFLUORO 3 METHYL 4 OXO 1,4 DIHYDROQUINOLIN 2 YL)PHENYL] 1H PYRROLE 2 CARBONITRILE; 2 [3 CHLORO (4 (1H PYRROL 1 YL)PHENYL] 5,7 DIFLUORO 3 METHYLQUINOLIN 4(1H) ONE; 2 [4 (1H INDOL 1 YL)PHENYL] 5,7 DIFLUORO 3 METHYLQUINOLIN 4(1H) ONE; 2 [4 (1H PYRAZOL 1 YL)PHENYL] 5,7 DIFLUORO 3 METHYLQUINOLIN 4(1H) ONE; 2 [4 (1H PYRROL 1 YL)PHENYL] 5 FLUORO 3 METHYLQUINOLIN 4(1H) ONE; 2 [4 (1H PYRROL 1 YL)PHENYL] 5,7 DIFLUORO 3 METHYLQUINOLIN 4(1H) ONE; 2 [4 (3,3 DIFLUOROAZETIDIN 1 YL)PHENYL] 5,7 DIFLUORO 3 METHYLQUINOLIN 4(1H) ONE; 2 [4 (3,4 DIFLUORO 1H PYRROL 1 YL)PHENYL] 5,7 DIFLUORO 3 METHYLQUINOLIN 4(1H) ONE; 2 [4 (3,4 DIFLUORO 1H PYRROL 1 YL)PHENYL] 7 METHOXY 3 METHYLQUINOLIN 4(1H) ONE; 2 [4 (4 FLUOROPIPERIDIN 1 YL)PHENYL] 3 METHYLQUINOLIN 4(1H) ONE; 2 [4 (4 FLUOROPIPERIDIN 1 YL)PHENYL] 7 METHOXY 3 METHYLQUINOLIN 4(1H) ONE; 3 METHYL 2 [4 (PIPERIDIN 1 YL)PHENYL]QUINOLIN 4(1H) ONE; 5,7 DIFLUORO 2 [2 FLUORO 4 (1H PYRROL 1 YL)PHENYL] 3 METHYLQUINOLIN 4(1H) ONE; 5,7 DIFLUORO 2 [4 (3 FLUOROPYRROLIDIN 1 YL)PHENYL] 3 METHYLQUINOLIN 4(1H) ONE; 5,7 DIFLUORO 2 [4 (4 FLUOROPIPERIDIN 1 YL)PHENYL] 3 METHYLQUINOLIN 4(1H) ONE; 5,7 DIFLUORO 3 METHYL 2 [4 (PIPERIDIN 1 YL)PHENYL]QUINOLIN 4(1H) ONE; 5,7 DIMETHOXY 3 METHYL 2 [4 (PIPERIDIN 1 YL)PHENYL]QUINOLIN 4(1H) ONE; 6 CHLORO 7 METHOXY 3 METHYL 2 [4 (PIPERIDIN 1 YL)PHENYL]QUINOLIN 4(1H) ONE; 6 FLUORO 3 METHYL 2 [4 (PIPERIDIN 1 YL)PHENYL]QUINOLIN 4(1H) ONE; 6 FLUORO 7 METHOXY 3 METHYL 2 [4 (PIPERIDIN 1 YL)PHENYL]QUINOLIN 4(1H) ONE; 6,7 DIMETHOXY 3 METHYL 2 [4 (PIPERIDIN 1 YL)PHENYL]QUINOLIN 4(1H) ONE; 7 CHLORO 3 METHYL 2 [4 (PIPERIDIN 1 YL)PHENYL]QUINOLIN 4(1H) ONE; 7 FLUORO 3 METHYL 2 [4 (PIPERIDIN 1 YL)PHENYL]QUINOLIN 4(1H) ONE; 7 METHOXY 3 METHYL 2 [4 (PIPERIDIN 1 YL)PHENYL]QUINOLIN 4(1H) ONE; HETEROCYCLIC QUINOLONE DERIVATIVE; OXIDOREDUCTASE; PHENOTHIAZINE; QUINOLONE DERIVATIVE; THIORIDAZINE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; IC50; MYCOBACTERIUM TUBERCULOSIS; PHARMACOPHORE; RESPIRATORY CHAIN; ANIMAL; CACO-2 CELL LINE; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMISTRY; DRUG EFFECTS; ELECTRON TRANSPORT; ELECTROSPRAY MASS SPECTROMETRY; HEP-G2 CELL LINE; METABOLISM; MICROBIAL SENSITIVITY TEST; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TOXICITY TESTING;

ANIMALS; CACO-2 CELLS; CARBON-13 MAGNETIC RESONANCE SPECTROSCOPY; DRUG DESIGN; ELECTRON TRANSPORT; HEP G2 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PROTON MAGNETIC RESONANCE SPECTROSCOPY; QUINOLONES; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; TOXICITY TESTS;

EID: 85019208674     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01718     Document Type: Article

References (63)

1. Global Tuberculosis Report 2015: Executive Summary, 20th ed.; World Health Organisation: Geneva, Switzerland, 2015; pp 1-4.
2. Streicher, E. M.; Müller, B.; Chihota, V.; Mlambo, C.; Tait, M.; Pillay, M.; Trollip, A.; Hoek, K. G. P.; Sirgel, F. A.; Gey van Pittius, N. C.; van Helden, P. D.; Victor, T. C.; Warren, R. M. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa Infect., Genet. Evol. 2012, 12, 686-694 10.1016/j.meegid.2011.07.019
3. Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K. The challenge of new drug discovery for tuberculosis Nature 2011, 469, 483-490 10.1038/nature09657
4. Goel, D. Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis J. Pharmacol. Pharmacother. 2014, 5, 76-78 10.4103/0976-500X.124435
5. Guillemont, J.; Meyer, C.; Poncelet, A.; Bourdrez, X.; Andries, K. Diarylquinolines, synthesis pathways and quantitative structure-activity relationship studies leading to the discovery of TMC207 Future Med. Chem. 2011, 3, 1345-1360 10.4155/fmc.11.79
6. Xavier, A. S.; Lakshmanan, M. Delamanid: A new armor in combating drug-resistant tuberculosis J. Pharmacol. Pharmacother. 2014, 5, 222-224 10.4103/0976-500X.136121
7. Matsumoto, M.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Tsubouchi, H.; Sasaki, H.; Shimokawa, Y.; Komatsu, M. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice PLoS Med. 2006, 3, e466 10.1371/journal.pmed.0030466
8. Fox, G. J.; Menzies, D. A Review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis Infect. Dis. Ther. 2013, 2, 123-144 10.1007/s40121-013-0009-3
9. Weinstein, E. A.; Yano, T.; Li, L. S.; Avarbock, D.; Avarbock, A.; Helm, D.; McColm, A. A.; Duncan, K.; Lonsdale, J. T.; Rubin, H. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 4548-4553 10.1073/pnas.0500469102
10. Koul, A.; Dendouga, N.; Vergauwen, K.; Molenberghs, B.; Vranckx, L.; Willebrords, R.; Ristic, Z.; Lill, H.; Dorange, I.; Guillemont, J.; Bald, D.; Andries, K. Diarylquinolines target subunit c of mycobacterial ATP synthase Nat. Chem. Biol. 2007, 3, 323-324 10.1038/nchembio884
11. Haagsma, A. C.; Abdillahi-Ibrahim, R.; Wagner, M. J.; Krab, K.; Vergauwen, K.; Guillemont, J.; Andries, K.; Lill, H.; Koul, A.; Bald, D. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue Antimicrob. Agents Chemother. 2009, 53, 1290-1292 10.1128/AAC.01393-08
12. Koul, A.; Vranckx, L.; Dendouga, N.; Balemans, W.; Van den Wyngaert, I.; Vergauwen, K.; Gohlmann, H. W.; Willebrords, R.; Poncelet, A.; Guillemont, J.; Bald, D.; Andries, K. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis J. Biol. Chem. 2008, 283, 25273-25280 10.1074/jbc.M803899200
13. Diacon, A. H.; Pym, A.; Grobusch, M.; Patientia, R.; Rustomjee, R.; Page-Shipp, L.; Pistorius, C.; Krause, R.; Bogoshi, M.; Churchyard, G.; Venter, A.; Allen, J.; Palomino, J. C.; De Marez, T.; van Heeswijk, R. P.; Lounis, N.; Meyvisch, P.; Verbeeck, J.; Parys, W.; de Beule, K.; Andries, K.; McNeeley, D. F. The diarylquinoline TMC207 for multidrug-resistant tuberculosis N. Engl. J. Med. 2009, 360, 2397-2405 10.1056/NEJMoa0808427
14. Warman, A. J.; Rito, T. S.; Fisher, N. E.; Moss, D. M.; Berry, N. G.; O’Neill, P. M.; Ward, S. A.; Biagini, G. A. Antitubercular pharmacodynamics of phenothiazines J. Antimicrob. Chemother. 2013, 68, 869-880 10.1093/jac/dks483
15. Pethe, K.; Bifani, P.; Jang, J.; Kang, S.; Park, S.; Ahn, S.; Jiricek, J.; Jung, J.; Jeon, H. K.; Cechetto, J.; Christophe, T.; Lee, H.; Kempf, M.; Jackson, M.; Lenaerts, A. J.; Pham, H.; Jones, V.; Seo, M. J.; Kim, Y. M.; Seo, M.; Seo, J. J.; Park, D.; Ko, Y.; Choi, I.; Kim, R.; Kim, S. Y.; Lim, S.; Yim, S.-A.; Nam, J.; Kang, H.; Kwon, H.; Oh, C.-T.; Cho, Y.; Jang, Y.; Kim, J.; Chua, A.; Tan, B. H.; Nanjundappa, M. B.; Rao, S. P. S.; Barnes, W. S.; Wintjens, R.; Walker, J. R.; Alonso, S.; Lee, S.; Kim, J.; Oh, S.; Oh, T.; Nehrbass, U.; Han, S.-J.; No, Z.; Lee, J.; Brodin, P.; Cho, S.-N.; Nam, K.; Kim, J. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis Nat. Med. 2013, 19, 1157-1160 10.1038/nm.3262
16. Abrahams, K. A.; Cox, J. A.; Spivey, V. L.; Loman, N. J.; Pallen, M. J.; Constantinidou, C.; Fernandez, R.; Alemparte, C.; Remuinan, M. J.; Barros, D.; Ballell, L.; Besra, G. S. Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB PLoS One 2012, 7, e52951 10.1371/journal.pone.0052951
17. Kana, B. D.; Machowski, E. E.; Schechter, N.; Shin, J.-T.; Rubin, H.; Mizrahi, V. Electron transport and respiration. In Mycobacterium: Genomics and Molecular Biology; Parish, T.; Brown, A., Eds.; Horizon Press, London, UK, 2009; pp 35-64.
18. Rao, S. P. S.; Alonso, S.; Rand, L.; Dick, T.; Pethe, K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 11945-11950 10.1073/pnas.0711697105
19. Lloyd, D.; Hayes, A. J. Vigor, vitality and viability of microorganisms FEMS Microbiol. Lett. 1995, 133, 1-7 10.1111/j.1574-6968.1995.tb07852.x
20. Griffin, J. E.; Gawronski, J. D.; DeJesus, M. A.; Ioerger, T. R.; Akerley, B. J.; Sassetti, C. M. High-resolution phenotypic profiling defines genes essential for Mycobacterial growth and cholesterol catabolism PLoS Pathog. 2011, 7, e1002251 10.1371/journal.ppat.1002251
21. Awasthy, D.; Ambady, A.; Narayana, A.; Morayya, S.; Sharma, U. Roles of the two type II NADH dehydrogenases in the survival of Mycobacterium tuberculosis in vitro Gene 2014, 550, 110-116 10.1016/j.gene.2014.08.024
22. Betts, J. C.; Lukey, P. T.; Robb, L. C.; McAdam, R. A.; Duncan, K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling Mol. Microbiol. 2002, 43, 717-731 10.1046/j.1365-2958.2002.02779.x
23. Winder, F. G.; Collins, P. B. Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis J. Gen. Microbiol. 1970, 63, 41-48 10.1099/00221287-63-1-41
24. Brennan, P. J.; Crick, D. C. The cell-wall core of mycobacterium tuberculosis in the context of drug discovery Curr. Top. Med. Chem. 2007, 7, 475-488 10.2174/156802607780059763
25. Mdluli, K.; Ma, Z. Mycobacterium tuberculosis DNA Gyrase as a target for drug discovery Infect. Disord.: Drug Targets 2007, 7, 159-168 10.2174/187152607781001763
26. Aubry, A.; Pan, X.-S.; Fisher, L. M.; Jarlier, V.; Cambau, E. Mycobacterium tuberculosis DNA Gyrase: Interaction with quinolones and correlation with antimycobacterial drug activity Antimicrob. Agents Chemother. 2004, 48, 1281-1288 10.1128/AAC.48.4.1281-1288.2004
27. Shi, W.; Zhang, X.; Jiang, X.; Yuan, H.; Lee, J. S.; Barry, C. E.; Wang, H.; Zhang, W.; Zhang, Y. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis Science 2011, 333, 1630-1632 10.1126/science.1208813
28. Campbell, E. A.; Korzheva, N.; Mustaev, A.; Murakami, K.; Nair, S.; Goldfarb, A.; Darst, S. A. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase Cell 2001, 104, 901-912 10.1016/S0092-8674(01)00286-0
29. Fisher, N.; Warman, A. J.; Ward, S. A.; Biagini, G. A. Chapter 17 Type II NADH: quinone oxidoreductases of Plasmodium falciparum and Mycobacterium tuberculosis kinetic and high-throughput assays Methods Enzymol. 2009, 456, 303-320 10.1016/S0076-6879(08)04417-0
30. Warman, A. J.; Rito, T. S.; Fisher, N. E.; Moss, D. M.; Berry, N. G.; O’Neill, P. M.; Ward, S. A.; Biagini, G. A. Antitubercular pharmacodynamics of phenothiazines J. Antimicrob. Chemother. 2013, 68, 869-880 10.1093/jac/dks483
31. Kristiansen, J. E.; Dastidar, S. G.; Palchoudhuri, S.; Roy, D. S.; Das, S.; Hendricks, O.; Christensen, J. B. Phenothiazines as a solution for multidrug resistant tuberculosis: From the origin to present Int. Microbiol. 2015, 18, 1-12 10.2436/20.1501.01.229
32. Durant, J. L.; Leland, B. A.; Henry, D. R.; Nourse, J. G. Reoptimization of MDL keys for use in drug discovery J. Chem. Inf. Comput. Sci. 2002, 42, 1273-1280 10.1021/ci010132r
33. Willett, P. Similarity-based virtual screening using 2D fingerprints Drug Discovery Today 2006, 11, 1046-1053 10.1016/j.drudis.2006.10.005
34. Geppert, H.; Vogt, M.; Bajorath, J. Current trends in ligand-based virtual screening: molecular representations, data mining methods, new application areas, and performance evaluation J. Chem. Inf. Model. 2010, 50, 205-216 10.1021/ci900419k
35. Liu, K.; Feng, J.; Young, S. S. PowerMV: a software environment for molecular viewing, descriptor generation, data analysis and hit evaluation J. Chem. Inf. Model. 2005, 45, 515-522 10.1021/ci049847v
36. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 2000, 44, 235-249 10.1016/S1056-8719(00)00107-6
37. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002, 45, 2615-2623 10.1021/jm020017n
38. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 2008, 51, 817-834 10.1021/jm701122q
39. Hughes, J. D.; Blagg, J.; Price, D. A.; Bailey, S.; DeCrescenzo, G. A.; Devraj, R. V.; Ellsworth, E.; Fobian, Y. M.; Gibbs, M. E.; Gilles, R. W.; Greene, N.; Huang, E.; Krieger-Burke, T.; Loesel, J.; Wager, T.; Whiteley, L.; Zhang, Y. Physiochemical drug properties associated with in vivo toxicological outcomes Bioorg. Med. Chem. Lett. 2008, 18, 4872-4875 10.1016/j.bmcl.2008.07.071
40. Waring, M. J. Lipophilicity in drug discovery Expert Opin. Drug Discovery 2010, 5, 235-248 10.1517/17460441003605098
41. Pidathala, C.; Amewu, R.; Pacorel, B.; Nixon, G. L.; Gibbons, P.; Hong, W. D.; Leung, S. C.; Berry, N. G.; Sharma, R.; Stocks, P. A.; Srivastava, A.; Shone, A. E.; Charoensutthivarakul, S.; Taylor, L.; Berger, O.; Mbekeani, A.; Hill, A.; Fisher, N. E.; Warman, A. J.; Biagini, G. A.; Ward, S. A.; O’Neill, P. M. Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum Type II NADH:quinone oxidoreductase (PfNDH2) J. Med. Chem. 2012, 55, 1831-1843 10.1021/jm201179h
42. Leung, S. C.; Gibbons, P.; Amewu, R.; Nixon, G. L.; Pidathala, C.; Hong, W. D.; Pacorel, B.; Berry, N. G.; Sharma, R.; Stocks, P. A.; Srivastava, A.; Shone, A. E.; Charoensutthivarakul, S.; Taylor, L.; Berger, O.; Mbekeani, A.; Hill, A.; Fisher, N. E.; Warman, A. J.; Biagini, G. A.; Ward, S. A.; O’Neill, P. M. Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum Type II NADH:quinone oxidoreductase (PfNDH2) J. Med. Chem. 2012, 55, 1844-1857 10.1021/jm201184h
43. Biagini, G. A.; Fisher, N.; Shone, A. E.; Mubaraki, M. A.; Srivastava, A.; Hill, A.; Antoine, T.; Warman, A. J.; Davies, J.; Pidathala, C.; Amewu, R. K.; Leung, S. C.; Sharma, R.; Gibbons, P.; Hong, D. W.; Pacorel, B.; Lawrenson, A. S.; Charoensutthivarakul, S.; Taylor, L.; Berger, O.; Mbekeani, A.; Stocks, P. A.; Nixon, G. L.; Chadwick, J.; Hemingway, J.; Delves, M. J.; Sinden, R. E.; Zeeman, A.-M.; Kocken, C. H. M.; Berry, N. G.; O’Neill, P. M.; Ward, S. A. Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 8298-8303 10.1073/pnas.1205651109
44. Sharma, R.; Lawrenson, A. S.; Fisher, N. E.; Warman, A. J.; Shone, A. E.; Hill, A.; Mbekeani, A.; Pidathala, C.; Amewu, R. K.; Leung, S.; Gibbons, P.; Hong, D. W.; Stocks, P.; Nixon, G. L.; Chadwick, J.; Shearer, J.; Gowers, I.; Cronk, D.; Parel, S. P.; O’Neill, P. M.; Ward, S. A.; Biagini, G. A.; Berry, N. G. Identification of novel antimalarial chemotypes via chemoinformatic compound selection methods for a high-throughput screening program against the novel malarial target, PfNDH2: Increasing hit rate via virtual screening methods J. Med. Chem. 2012, 55, 3144-3154 10.1021/jm3001482
45. Nilsen, A.; LaCrue, A. N.; White, K. L.; Forquer, I. P.; Cross, R. M.; Marfurt, J.; Mather, M. W.; Delves, M. J.; Shackleford, D. M.; Saenz, F. E.; Morrisey, J. M.; Steuten, J.; Mutka, T.; Li, Y.; Wirjanata, G.; Ryan, E.; Duffy, S.; Kelly, J. X.; Sebayang, B. F.; Zeeman, A. M.; Noviyanti, R.; Sinden, R. E.; Kocken, C. H.; Price, R. N.; Avery, V. M.; Angulo-Barturen, I.; Jimenez-Diaz, M. B.; Ferrer, S.; Herreros, E.; Sanz, L. M.; Gamo, F. J.; Bathurst, I.; Burrows, J. N.; Siegl, P.; Guy, R. K.; Winter, R. W.; Vaidya, A. B.; Charman, S. A.; Kyle, D. E.; Manetsch, R.; Riscoe, M. K. Quinolone-3-diarylethers: a new class of antimalarial drug Sci. Transl. Med. 2013, 5, 177ra37 10.1126/scitranslmed.3005029
46. Nilsen, A.; Miley, G. P.; Forquer, I. P.; Mather, M. W.; Katneni, K.; Li, Y.; Pou, S.; Pershing, A. M.; Stickles, A. M.; Ryan, E.; Kelly, J. X.; Doggett, J. S.; White, K. L.; Hinrichs, D. J.; Winter, R. W.; Charman, S. A.; Zakharov, L. N.; Bathurst, I.; Burrows, J. N.; Vaidya, A. B.; Riscoe, M. K. Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers J. Med. Chem. 2014, 57, 3818-3834 10.1021/jm500147k
47. Monastyrskyi, A.; Kyle, D. E.; Manetsch, R. 4(1H)-Pyridone and 4(1H)-quinolone derivatives as antimalarials with erythrocytic, exoerythrocytic, and transmission blocking activities Curr. Top. Med. Chem. 2014, 14, 1693-1705 10.2174/1568026614666140808124638
48. Monastyrskyi, A.; LaCrue, A. N.; Mutka, T. S.; Sakhno, Y.; Kyle, D. E.; Manetsch, R. Synthesis and evaluation of 4(1H)-quinolone prodrugs targeting multi-drug resistance P. falciparum malaria. 245th ACS National Meeting New Orleans, LA, April 7-11, 2013; American Chemical Society: Washington, DC, 2013; MEDI-388.
49. Bueno, J. M.; Herreros, E.; Angulo-Barturen, I.; Ferrer, S.; Fiandor, J. M.; Gamo, F. J.; Gargallo-Viola, D.; Derimanov, G. Exploration of 4(1H)-pyridones as a novel family of potent antimalarial inhibitors of the plasmodial cytochrome bc1 Future Med. Chem. 2012, 4, 2311-2323 10.4155/fmc.12.177
50. Charoensutthivarakul, S.; David Hong, W.; Leung, S. C.; Gibbons, P. D.; Bedingfield, P. T. P.; Nixon, G. L.; Lawrenson, A. S.; Berry, N. G.; Ward, S. A.; Biagini, G. A.; O’Neill, P. M. 2-Pyridylquinolone antimalarials with improved antimalarial activity and physicochemical properties MedChemComm 2015, 6, 1252-1259 10.1039/C5MD00062A
51. Marwaha, J.; Palmer, M.; Hoffer, B.; Freedman, R.; Rice, K.; Paul, S.; Skolnick, P. Differential electrophysiological and behavioral responses to optically active derivatives of phencyclidine Naunyn-Schmiedeberg's Arch. Pharmacol. 1981, 315, 203-209 10.1007/BF00499836
52. Antilla, J. C.; Baskin, J. M.; Barder, T. E.; Buchwald, S. L. Copper-diamine-catalyzed N-arylation of pyrroles, pyrazoles, indazoles, imidazoles, and triazoles J. Org. Chem. 2004, 69, 5578-5587 10.1021/jo049658b
53. Antilla, J. C.; Klapars, A.; Buchwald, S. L. The copper-catalyzed N-arylation of indoles J. Am. Chem. Soc. 2002, 124, 11684-11688 10.1021/ja027433h
54. Kerekes, A. D.; Esposite, S. J.; Doll, R. J.; Tagat, J. R.; Yu, T.; Xiao, Y.; Zhang, Y.; Prelusky, D. B.; Tevar, S.; Gray, K.; Terracina, G. A.; Lee, S.; Jones, J.; Liu, M.; Basso, A. D.; Smith, E. B. Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: Fluorine and deuterium incorporation improve oral absorption and exposure J. Med. Chem. 2011, 54, 201-210 10.1021/jm1010995
55. Klapars, A.; Buchwald, S. L. Copper-catalyzed halogen exchange in aryl halides: An aromatic Finkelstein reaction J. Am. Chem. Soc. 2002, 124, 14844-14845 10.1021/ja028865v
56. Taniguchi, T.; Kawada, A.; Kondo, M.; Quinn, J. F.; Kunitomo, J.; Yoshikawa, M.; Fushimi, M. Preparation of pyridazinone compounds as phosphodiesterase 10A inhibitors for preventing and treating schizophrenia. US20100197651A1, 2010.
57. Miley, G. P.; Pou, S.; Winter, R.; Nilsen, A.; Li, Y. X.; Kelly, J. X.; Stickles, A. M.; Mather, M. W.; Forquer, I. P.; Pershing, A. M.; White, K.; Shackleford, D.; Saunders, J.; Chen, G.; Ting, L. M.; Kim, K.; Zakharov, L. N.; Donini, C.; Burrows, J. N.; Vaidya, A. B.; Charman, S. A.; Riscoe, M. K. ELQ-300 prodrugs for enhanced delivery and single-dose cure of Malaria Antimicrob. Agents Chemother. 2015, 59, 5555-5560 10.1128/AAC.01183-15
58. Wayne, L. G.; Hayes, L. G. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence Infect. Immun. 1996, 64, 2062-2069
59. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 1983, 65, 55-63 10.1016/0022-1759(83)90303-4
60. Marroquin, L. D.; Hynes, J.; Dykens, J. A.; Jamieson, J. D.; Will, Y. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants Toxicol. Sci. 2007, 97, 539-547 10.1093/toxsci/kfm052
61. Moss, D. M.; Kwan, W. S.; Liptrott, N. J.; Smith, D. L.; Siccardi, M.; Khoo, S. H.; Back, D. J.; Owen, A. Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir Antimicrob. Agents Chemother. 2011, 55, 879-887 10.1128/AAC.00623-10
62. Elsby, R.; Surry, D. D.; Smith, V. N.; Gray, A. J. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions Xenobiotica 2008, 38, 1140-1164 10.1080/00498250802050880
63. Neely, M. N.; van Guilder, M. G.; Yamada, W. M.; Schumitzky, A.; Jelliffe, R. W. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R Ther. Drug Monit. 2012, 34, 467-476 10.1097/FTD.0b013e31825c4ba6